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Background: In the randomized HORIZONS-AMI trial, implantation of paclitaxel-eluting stents (PES) as compared to bare-metal stents (BMS) in 
pts with STEMI significantly reduced recurrent ischemia, with similar rates of death, reinfarction and stent thrombosis (ST). We assessed the impact 
of diabetes mellitus (DM) on clinical outcomes at 3 years in this trial.
Methods: In HORIZONS-AMI, 3,006 pts were randomized in a 3:1 ratio to receive PES or BMS, stratified by the presence of DM at the time 
of admission. Ischemia-driven target lesion (TLR) or target vessel revascularization (TVR), major adverse cardiovascular events (MACE: death, 
reinfarction, ischemic TVR or stroke) and ST were assessed according to diabetic status at 3 years.
Results: Of the 3,006 randomized pts, 478 (15.9%) presented with DM. The 3-year rates of reinfarction (8.9 vs. 6.5%, p=0.09) and ST (6.0% vs. 
4.7%, p=0.27) were comparable between DM vs. non-DM pts, whereas death (10.3% vs. 5.0%, p<0.0001), stroke (3.1% vs. 1.3%, p=0.004), TLR 
(14.2% vs. 10.8%, p=0.04), TVR (17.5% vs. 13.9%, p=0.04) and non-TVR (16.4% vs. 9.6%, p<0.0001) occurred significantly more often in DM pts. 
Outcomes at 3 years according to stent randomization are shown in the Table.
Conclusions: In the HORIZONS-AMI trial, implantation of PES compared to BMS in diabetic pts resulted in a 70% reduction in TLR, 61% reduction 
in TVR and a 46% reduction in MACE at 3 years, with comparable rates of safety outcomes including ST. The absolute benefits of PES were greater in 
DM than non-DM pts. 
Diabetics Non-Diabetics
PES
n=364
BMS
n=114
P=
PES
n=1892
BMS
n=635
P=
TLR 9.7% 29.5% <0.0001 9.4% 12.7% 0.02
TVR 13.4% 31.3% <0.0001 12.2% 15.3% 0.04
Cardiac death 7.0% 6.5% 0.85 2.5% 3.4% 0.24
Reinfarction 8.9% 8.8% 0.96 6.6% 6.2% 0.76
MACE 24.8% 41.5% <0.001 19.0% 21.0% 0.27
Stent thrombosis (def/prob) 5.8% 6.6% 0.73 5.0% 4.0% 0.38
